Genomic profiling for clinical decision making in lymphoid neoplasms

Area of Science:

• Hematology
• Genomics
• Oncology

Background:

• Large-scale molecular profiling and high-throughput sequencing have detailed genomic features of lymphoid neoplasms.
• Current lymphoid tumor diagnosis relies mainly on morphology and immunophenotyping, with limited genomic criteria.
• Novel genomic data significantly enhance understanding of lymphomagenesis and disease entities.

Purpose of the Study:

• To review how molecular testing complements clinical diagnoses and refines classification of mature lymphoid neoplasms.
• To discuss the contributions of molecular testing to diagnosis refinement, risk stratification, and therapy prediction.
• To explore future applications of advanced genomic technologies in precision medicine for lymphoid malignancies.

Main Methods:

• Review of established and emerging molecular testing technologies.
• Analysis of genomic data from large-scale molecular profiling and high-throughput sequencing.
• Discussion of potential applications of whole-genome sequencing, ctDNA, single-cell, and epigenetic analyses.

Main Results:

• Molecular testing already complements current diagnostic methods for lymphoid neoplasms.
• Genomic insights are enriching disease entity descriptions and improving understanding of lymphomagenesis.
• Established and novel molecular assays contribute to diagnosis refinement, risk stratification, and therapy prediction.

Conclusions:

• Genomic data are crucial for advancing the classification and understanding of mature lymphoid neoplasms.
• Molecular testing plays an increasingly important role in refining diagnoses and guiding treatment decisions.
• Future genomic technologies promise to enable personalized medicine approaches for lymphoid malignancies.